26 publications
Name | Date | Type | Actions |
---|---|---|---|
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
Public releases | ||
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
Public releases | ||
First half Results 2013 Half year results |
Half Year Report | ||
Half year financial report 2013 2013 Half year Financial Report |
Half Year Report | ||
The reference products demonstrate solid growth Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013. |
Public releases | ||
Q2 2013 sales Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like. |
Public releases | ||
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version) The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013. |
Public releases | ||
Q1 2013 sales Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
Public releases | ||
2012, return to growth Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements. |
Public releases | ||
2012 sales up 5.0% Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%. |
Public releases | ||
Vétoquinol announces opening of its first decentralized R&D center in Canada |
Public releases | ||
Vétoquinol to market and distribute Vetprofen in the United States |
Public releases | ||
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
Public releases | ||
Reports very good first half, confirming that 2007 performance is set to surpass targets |
Public releases | ||
Presentation of Vétoquinol’s results for the first half of 2007 2007 Half year results |
Public releases | ||
Etats financiers consolidés du 1er semestre 2007 (french) |
Half Year Report | ||
Rapport semestriel 2007 « narratif » (french) Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un |
Public releases | ||
Business is strong in first-half of 2007 : + 12.9% 2007 Half year Financial Report |
Public releases | ||
Vétoquinol creates a subsidiary in Portugal |
Public releases | ||
2006 Financial Report Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent. |
Public releases | ||
Activity Report 2006 |
Public releases | ||
Annual earnings for 2006: a year of good performance |
Public releases | ||
Présentation des résultats 2006 de Vétoquinol (french) |
Public releases | ||
Vétoquinol reports one of its industry’ strongest growth performances in 2006 |
Public releases | ||
Sustained revenue growth in 2006 |
Public releases | ||
Vétoquinol strengthens its position in the United States |
Public releases |